Skip to content
type1.science

Ypsomed mylife Loop (CamAPS FX on YpsoPump)

Ypsomed (with CamDiab and Dexcom/Abbott)

Ypsomed's commercial AID bundle: the tubed YpsoPump driven by CamDiab's adaptive CamAPS FX algorithm app, paired with a Dexcom or FreeStyle Libre sensor. From the user's perspective it is the same self-learning hybrid closed loop as CamAPS FX, sold as one integrated, phone-controlled package across the UK and EU — and uniquely licensed down to age 1 and through pregnancy.

Available nowStrong evidencehybrid-closed-looptubedphone-controlOfficial site ↗

The scorecard

Time in range74

Achieved real-world TIR of 69.6% (median, IQR 61.3-77.2) across 35,714 T1D users in 19 countries (Boughton et al., Metabologia 2026) is the most representative figure; a smaller 1,805-user real-world analysis reported a higher 72.6% ± 11.5%. By age, real-world TIR spans ~62.5% (young adults 18-22y) to ~76.1% (≥65y). Weighting toward the large, broad, multi-age cohort at ~70% places CamAPS FX at 74 on the achieved-TIR scale calibrated to the MiniMed 780G anchor (~76% = 80) — genuinely below the 780G anchor, kept conservative because the dominant dataset sits at ~70% rather than the smaller cohort's ~73%.[1]

Hypo protection76

Achieved real-world time-below-70 mg/dL (<3.9 mmol/L) was 2.5% (median, IQR 1.4-3.9) in the 35,714-user cohort and 2.3% (IQR 1.3-3.6) in the 1,805-user cohort, staying <4% across every age group. A TBR of ~2.3-2.5% maps to the 76-78 band (the calibration places ~2-2.5% at 76-78, ~3% at 72-74); CamAPS FX's well-controlled hypoglycemia at scale supports 76.[1]

Automation level70

Self-learning MPC algorithm runs ~95% in closed-loop and adapts continuously; on this bundle, simplified meal announcement was non-inferior to full carb counting, but meals are still announced (hybrid).

Average glucose74

Achieved GMI was 7.1% ± 0.5% (mean glucose 8.7 mmol/L) in the 35,714-user real-world cohort and 6.9% (mean glucose 8.4 mmol/L) in the 1,805-user cohort. A GMI near 7.1% reflects solid but not class-leading average-glucose control, consistent with the ~70% achieved TIR; scored 74 to align with the time-in-range anchor.[1]

Low variability73

Glycemic variability is not reported as a coefficient of variation in the primary real-world dataset, but the consistent TBR (~2.5%) alongside a ~70% TIR and GMI 7.1% across a 35,714-user, all-ages cohort indicates good day-to-day stability without exceptional tightening. Scored 73, slightly below the TIR anchor to reflect the absence of a directly reported low-CV figure and the conservative read of the larger cohort.[1]

Exercise handling71

Built-in Ease-off (raises target to reduce insulin for activity) and Boost modes give flexible, user-triggered exercise handling on top of fully adjustable targets.

Customizability78

Inherits CamAPS FX's unusually deep adjustability for a commercial product: freely settable personal targets plus Ease-off/Boost, a strength of the app-based model.

Access & cost54

Available on prescription across the UK and much of the EU (and now Australia/NZ via the 2025 iOS rollout), but not in the US; availability and sensor choice vary by country.

Freedom (form factor)54

Runs on the small, light tubed YpsoPump — discreet for a tubed system, but with tubing and a separate body.

Glycemic criteria are scored on the levels actually achieved in large real-world Type 1 diabetes cohorts — not the headline improvement over a trial's baseline (an improvement that looks bigger when the starting population was doing poorly). Type 2 diabetes trial data is never used to score a Type 1 system; where only improvement data exists, it informs the rationale, not the score. Freedom captures form factor and wearability, so a tubeless system is rewarded for the mobility a tubed one can't match.

The full picture

Ypsomed mylife Loop is the commercial bundle that packages the CamAPS FX algorithm onto Ypsomed's hardware. It is, from a user's day-to-day standpoint, the same self-learning hybrid closed loop as CamAPS FX — we list it as a distinct commercial system because the components, regulatory footprint and access differ from a generic "CamAPS deployment."

Components. Three pieces work as one system: the tubed mylife YpsoPump (a small 83 g pump using a 160-unit / 1.6 mL cartridge of rapid-acting analog),1 the CamAPS FX app (CamDiab's adaptive model-predictive-control algorithm, the "brain"),2 and a continuous glucose sensor — Dexcom G6/G7 or Abbott FreeStyle Libre 3.3 The whole loop is driven and bolused from the user's smartphone.4

Pivotal trial outcomes. The CamAPS FX algorithm's strongest evidence is a multicenter randomized crossover trial in 74 very young children (ages 1-7). Over two 16-week periods, the closed loop raised time-in-range (70-180 mg/dL) by 8.7 percentage points versus a sensor-augmented pump, lowered mean glucose by 12.3 mg/dL and HbA1c by 0.4 points, and did not increase time in hypoglycemia; the system ran in closed-loop mode ~95% of the time.5 A trial run on this exact bundle — YpsoPump + Dexcom G6 + CamAPS FX ("mylife CamAPS FX") in youth and young adults — reported ~70% time-in-range with only ~1.8% time below 3.9 mmol/L.6

Automation level. This is a hybrid loop: meals are still announced. But that same YpsoPump bundle trial showed simplified meal announcement (rough meal sizes instead of exact carb counting) was non-inferior to full carbohydrate counting for time-in-range — a meaningful reduction in daily burden.6 Between meals the algorithm delivers automatic corrections and continuously re-learns the individual's insulin needs.2

Exercise modes. Two built-in functions handle activity: Ease-off temporarily raises the glucose target to ease back insulin before/during exercise, and Boost increases delivery when more insulin is needed.4

Ages & indications. The algorithm is licensed for type 1 diabetes from age 1 and up (depending on the sensor) and is the only loop algorithm specifically indicated for pregnancy — reflecting its dedicated very-young-children and pregnancy trial programs.37 Caregivers of very young children using it reported less fear of hypoglycemia and better well-being.8

Access. It is available on prescription across the UK and much of the EU. Following an iOS launch in 2025, Ypsomed and CamDiab expanded availability to 18 countries, adding Australia, New Zealand, France, Italy, Spain and others.3 It is not available in the US.

What's coming. Sensor support keeps widening (Dexcom G7 and FreeStyle Libre 3/3 Plus are now in scope),3 and full iOS support removed the previous Android-only constraint.3 Research continues into reducing meal burden further (the simplified-announcement work)6 and into the algorithm with faster insulins;9 the persistent ceiling, as for all hybrid loops, remains the speed of injected insulin and the need to announce meals at all.

References

  1. Ypsomed/mylife Diabetescare. mylife YpsoPump insulin pump — specifications (1.6 mL/160 U cartridge; 83 g). mylife Diabetescare (2025). https://www.mylife-diabetescare.com/en/products/infusion-systems/mylife-ypsopump-insulin-pump.html ↩

  2. Laesser CI, et al. Simplified meal announcement study (SMASH) using hybrid closed-loop insulin delivery — describes the adaptive CamAPS FX algorithm. Diabetologia (2025). https://pubmed.ncbi.nlm.nih.gov/39560745/ ↩ ↩2

  3. Ypsomed. Ypsomed and CamDiab expand availability of mylife CamAPS FX on iOS (sensors, ages, pregnancy indication, country rollout). Ypsomed press release (10 June 2025). https://www.ypsomed.com/en/news-insights/news/press-releases/news-reader-detail-page/ypsomed-and-camdiab-expand-availability-of-mylife-camaps-fx-on-ios ↩ ↩2 ↩3 ↩4 ↩5

  4. Ypsomed/mylife Diabetescare. YpsoPump with mylife Loop — smartphone control, Ease-off and Boost activity functions. mylife Diabetescare (2025). https://www.mylife-diabetescare.com/en/mylife-loop.html ↩ ↩2

  5. Ware J, et al. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes (CamAPS FX; TIR +8.7 pp, mean glucose −12.3 mg/dL, HbA1c −0.4 pp, no rise in hypoglycemia). N Engl J Med 386:209-219 (2022). https://doi.org/10.1056/NEJMoa2111673 ↩

  6. Laesser CI, et al. SMASH crossover trial on mylife CamAPS FX (YpsoPump, Dexcom G6): simplified meal announcement non-inferior to carb counting; TIR 69.9% vs 70.7%, time <3.9 mmol/L ~1.8%. Diabetologia 68(2):295-307 (2025). https://doi.org/10.1007/s00125-024-06319-w ↩ ↩2 ↩3

  7. Lee TTM, et al. AiDAPT: automated insulin delivery among pregnant women with type 1 diabetes (CamAPS FX) — study protocol. BMC Pregnancy Childbirth 22:282 (2022). https://doi.org/10.1186/s12884-022-04543-z ↩

  8. de Beaufort C, et al. Cambridge Hybrid Closed-Loop System in Very Young Children Reduces Caregivers' Fear of Hypoglycemia and Improves Well-Being. Diabetes Care 45(12):3050-3 (2022). https://doi.org/10.2337/dc22-0693 ↩

  9. Ware J, et al. Hybrid Closed-Loop with Faster Insulin Aspart vs Standard Insulin Aspart in Very Young Children (CamAPS FX; TIR ~64-65%). Diabetes Technol Ther 25(6):431-436 (2023). https://doi.org/10.1089/dia.2023.0042 ↩

What's next for this

  • →Widening sensor support (Dexcom G7 and FreeStyle Libre 3/3 Plus now in scope)
  • →Full iOS support removing the previous Android-only constraint · 2025
  • →Research into reducing meal burden further (simplified announcement) and the algorithm with faster insulins

Sources

  1. [1]Real-world evidence on the CamAPS FX hybrid closed-loop system in people living with type 1 diabetes · peer-reviewed · 2026-01-01
  2. [2]Real-World Evidence Analysis of a Hybrid Closed-Loop System (CamAPS FX, 1,805 users / 15 countries) · peer-reviewed · 2023-01-01
  3. [3]AiDAPT: Closed-Loop Insulin Delivery in Pregnant Women with Type 1 Diabetes (NEJM) · peer-reviewed · 2023-01-01
  4. [4]Long-term assessment of the NHS hybrid closed-loop real-world study in children and young people with type 1 diabetes (incl. CamAPS FX) · peer-reviewed · 2024-01-01